COVID-19 Variants and Treatment approaches with Bio-active Compounds of Gmelina arborea: Research work based on Docking Studies-Reference-Cited by-同舟云学术

COVID-19 Variants and Treatment approaches with Bio-active Compounds of Gmelina arborea: Research work based on Docking Studies

Published:2024-06-25 Issue: Volume: Page:2556-2560
ISSN:0974-360X
Container-title:Research Journal of Pharmacy and Technology
language:en
Short-container-title:RJPT

Author:

Pandey Rupesh Kumar¹,Pathak Manish Kumar²,Singh Lubhan¹,Pandey Priyanka³,Naumovich Vladislav⁴,Pathak Prateek⁴,Grishina Maria⁴

Affiliation:

1. Department of Pharmacology, Kharvel Subharti College of Pharmacy, Swami Vivekanand Subharti University, Meerut (U.P.)

2. Department of Pharmaceutical Chemistry, Kharvel Subharti College of Pharmacy, Swami Vivekanand Subharti University, Meerut (U.P.)

3. Department of Pharmaceutics, NKBR College of Pharmacy, Meerut (U.P.)

4. Laboratory of Computational Modeling of Drugs, Higher Medical and Biological School, South Ural State University, Chelyabinsk, Russia.

Abstract

Objective - COVID-19 is the black chapter in the history of the world. Currently, many countries are facing different waves of this pandemic but the problem in front of us is the frequent mutants. Some questions are also coming about how we will treat future coming viruses. Method - Our aim in this research work is to perform the Molecular docking of important bioactive compounds of Gmelina arborea i.e. arboreol, gmelanone, gmelinol and hentriacontanol to the active site of 3CLpro. Result/Conclusion - the docking studies strongly suggest that Gmelina arborea can be used in the disease management. The need is to explore the plant Gmelina arborea, which can give directions in treatment in various diseases including COVID-19.

Publisher

A and V Publications

Reference32 articles.

1. Pal M, Berhanu G, Desalegn C, Kandi V. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update. Cureus. 2020; 12(3): e7423. Published 2020 Mar 26. doi:10.7759/cureus.7423

2. Imbert I, Snijder EJ, Dimitrova M, Guillemot JC, Lécine P, Canard B. The SARS-Coronavirus PLnc domain of nsp3 as a replication/transcription scaffolding protein. Virus Res. 2008; 133(2): 136-148. doi:10.1016/j.virusres.2007.11.017

3. Huang N, Perez P, Kato T, et al. SARS-CoV-2 infection of the oral cavity and saliva. Nat Med 27; 892–903 (2021). https://doi.org/10.1038/s41591-021-01296-8

4. Ni W, Yang X, Yang D, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020; 24(1): 422. Published 2020 Jul 13. Doi: 10.1186/s13054-020-03120-0.

5. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/